BioCryst Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	89.74	104.71	110.64	304.77	504.39
Short-Term Investments	185.01	216.14	278.34	119.54	3.21
Cash & Short-Term Investments	274.75	320.85	388.99	424.31	507.6
Cash Growth	-14.37%	-17.52%	-8.33%	-16.41%	68.99%
Receivables	106.82	79.07	56.95	50.6	29.41
Inventory	5.4	8.09	28.68	27.53	15.79
Prepaid Expenses	17.18	13.75	19.54	12.59	9.99
Restricted Cash	0.2	0.21	1.8	1.47	3.35
Total Current Assets	404.35	421.97	495.97	516.5	566.14
Property, Plant & Equipment	18.99	19.79	20.91	15.42	15.19
Long-Term Investments	61.16	20.32	-	18.08	6.83
Other Long-Term Assets	29.66	28.34	0.08	-	-
Total Assets	514.16	490.42	516.96	550	588.15
Accounts Payable	15.83	11.64	20.89	14.36	27.81
Accrued Expenses	126.41	113.29	102.88	87.57	72.67
Current Portion of Long-Term Debt	38.46	32.68	23.57	-	-
Current Portion of Leases	1.63	2.77	2.65	2.37	1.82
Current Unearned Revenue	-	-	-	1.22	1.42
Other Current Liabilities	13.74	-	-	-	-
Total Current Liabilities	196.07	160.38	149.99	105.51	103.72
Long-Term Debt	427.23	795.92	811.27	733.28	585.46
Long-Term Leases	10.01	10.05	11.24	5.8	5.96
Total Liabilities	633.31	966.35	972.49	844.6	695.14
Common Stock	2.13	2.09	2.06	1.88	1.84
Additional Paid-In Capital	1,385	1,291	1,222	1,158	1,098
Retained Earnings	-1,506	-1,770	-1,681	-1,455	-1,208
Comprehensive Income & Other	0.04	0.92	1.34	0.03	0.18
Shareholders' Equity	-119.15	-475.93	-455.53	-294.6	-106.99
Total Liabilities & Equity	514.16	490.42	516.96	550	588.15
Total Debt	477.33	841.42	848.71	741.45	593.24
Net Cash (Debt)	-202.58	-520.57	-459.73	-317.14	-85.64
Net Cash Per Share	-0.93	-2.52	-2.39	-1.71	-0.48
Filing Date Shares Outstanding	250.8	208.96	206.15	188.45	184.66
Total Common Shares Outstanding	213.06	208.54	205.77	187.91	184.35
Working Capital	208.28	261.58	345.98	410.99	462.42
Book Value Per Share	-0.56	-2.28	-2.21	-1.57	-0.58
Tangible Book Value	-119.15	-475.93	-455.53	-294.6	-106.99
Tangible Book Value Per Share	-0.56	-2.28	-2.21	-1.57	-0.58
Machinery	7.41	8.41	7.66	6.53	5.84
Construction In Progress	-	0.1	-	-	-
Leasehold Improvements	10.44	10.36	10.21	10.14	9.83

Source: S&P Global Market Intelligence. Standard template. Financial Sources.